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Editorial: gut selective immunosuppression—is it a double
edged sword? Authors’ reply
The Editorial on the safety of vedolizumab by Sheridan and Doherty1
in response to our safety review2 is thoughtful and well balanced, but
there are post-marketing data on malignancy after >25 000 patient-
years of experience with vedolizumab that they do not mention.3
Post-marketing surveillance data should be interpreted with
caution. Nevertheless, the tendency to under-report malignancy in
patients exposed to novel therapy is likely to be lower than for other
adverse events. The study on 25 831 patient-years of post-marketing
exposure to vedolizumab reported 25 malignancies.3 Half (12/25) were
gastrointestinal and seven colorectal (including one adenoma), which is
about what one would expect in such a large cohort.4,5 Where reported,
vedolizumab exposure was of short duration (≤6 months’ treatment, or
after ≤7 infusions at the time of malignancy diagnosis). Confounding
factors included prior use of immunosupressants including anti-tumour
necrosis factor therapy, smoking history, and previous malignancy prior
to initiating treatment with vedolizumab.
Although a4b7 inhibition may affect intestinal NK cell activity, the
authors have not elaborated on what pro-malignant ‘theoretical con-
cerns’ that they vaguely intimate are at play. There is no biologically
plausible carcinogenic pathway that would be specifically activated by
a4b7 inhibition. Thus, vedolizumab is unlikely to have any greater
effect on the development of dysplasia than other immune modula-
tors. The frequencies of dysplasia in the trials and post-marketing data
are within the bounds of what one would expect in long-standing IBD.
It is conceivable that there is a minimum exposure time per patient to
identify any risk. Only time will tell. Meanwhile, watchfulness rather
than concern about the potential for vedolizumab to increase the risk
of gastrointestinal malignancy is appropriate.
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Editorial: the risk of cancer in patients with gastric intestinal
metaplasia
Gastric cancer is the fifth most common cancer worldwide, only pre-
ceded by malignancies of the breast, colorectum, lung and prostate.
Gastric cancer makes up for close to 7% of all human cancers.1 The glo-
bal annual incidence is 951,000 cases, 73% of which are noncardia
cancers.2 We have for long come to understand the most common
pathway of these cancers, via gland loss or atrophic gastritis, intestinal
metaplasia (IM), dysplasia to invasive cancer. Large cohort studies with
longer follow-up have confirmed these pathways.3-5 There is a marked
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association between disease stage at diagnosis and treatment outcome.
These factors together make gastric neoplasia theoretically suitable for
screening as well as for surveillance of early lesions. There are, however,
a number of hurdles to conquer for optimal benefit of screening and
surveillance. These include improved diagnosis. In Western countries,
there has been a lot of emphasis on endoscopic recognition of early
lesions of the oesophagus and colon, but we continue to miss approxi-
mately 12% of early cancers of the stomach despite use of the same
equipment.6 This requires more appropriate training and quality mea-
sures. Furthermore, as atrophic gastritis and intestinal metaplasia are
common conditions, we need appropriate tools to select those subjects
who may benefit most from surveillance and early intervention. The
international guidelines on management of premalignant gastric lesions
recommend using the OLGA or OLGIM classification for that purpose.7
We need further studies to identify the actual progression rates of
different degrees of atrophy and metaplasia in various populations. A
recent study in this journal provided such information. It was a retro-
spective study from Thailand on 91 patients with gastric intestinal
metaplasia.8 One of 81 patients with complete IM progressed to high-
grade dysplasia; 5 of 10 with incomplete IM progressed to dysplasia
or cancer. The main factors associated with progression were male sex
and incomplete IM, but not OLGA/OLGIM stage.8 This important
observation is in line with a recent study from Spain that followed 649
patients with premalignant gastric lesions for a mean of 12 years.9 In
total, 24 (3.7%) patients developed gastric cancer, a rate similar to
other studies.3 In comparison with complete IM, incomplete IM was
associated with a hazard ratio of 2.75 (95% confidence interval: 1.06-
6.26) for progression to cancer.9 These studies provide valuable addi-
tions to the existing literature, and ask for expansion with data from
other countries. Together, these will allow us in the near future to
update guidelines and improve the management of patients at risk of
an invasive cancer with poor prognosis.
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Editorial: the risk of cancer in patients with gastric intestinal
metaplasia—Authors’ reply
We thank Professor Kuipers for his valuable editorial1 on our ret-
rospective cohort study2 and accentuation of the burden of gastric
cancer, not only in high prevalence countries but all over the
world.
We agree that gastric cancer can be prevented by a strategy of
early diagnosis, especially in patients with precancerous lesions,
because of the well-known Correa pathway of gastric cancer.3 There
exists a 12% miss rate in diagnosing early gastric cancer in Western
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